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013.03.0Abstract The Brugada Syndrome (BrS) is a heterogeneous genetic disease characterized by persis-
tent or transient ST-segment elevation in the right precordial electrocardiography (ECG) leads and
a high incidence of sudden death and life-threatening ventricular tachyarrhythmias in patients with
structurally normal hearts. The syndrome generally manifests in men during adulthood. The ECG
manifestations can be overt or concealed. We report a case of BrS whose type 1 ECG pattern during
febrile state converted to type 2 ECG after alleviation of fever with atypical characteristics
(78-year-old woman with monomorphic ventricular tachycardia on holter monitoring, a history
of the sudden infant death of her child, and without inducible ventricular arrhythmia by programed
ventricular stimulation [PVS]).
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The Brugada Syndrome (BrS) is a heterogeneous genetic
disease characterized by persistent or transient ST-segmentazir Mahallesi Turgut O¨zal
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03elevation in the right precordial ECG leads and a high inci-
dence of sudden death and life-threatening ventricular tachyar-
rhythmias in patients with structurally normal hearts. It is
estimated to cause 4–12% of all sudden cardiac deaths and
up to 20% among patients without structural heart abnormal-
ities in some regions of the world.1 The syndrome is inherited
as an autosomal dominant trait. Since it was linked to muta-
tions in the SCN5A gene that encodes the a subunit of the car-
diac sodium channel protein, more than 80 mutations have
been linked to the syndrome in the SCN5A gene.2 Although
the genetic mutation is equally distributed between the sexes,
the clinical phenotype is 8–10 times more prevalent in males
than in females.3 The ECG manifestations can be overt or con-
cealed that can be unmasked by sodium channel blockers, dur-
ing a febrile state, or with vagotonic agents.2gyptian Society of Cardiology.
236 H. Ari et al.We report a case of BrS whose type 1 ECG pattern during
febrile state converted to type 2 ECG after alleviation of fever
with atypical characteristics (78-year-old woman with mono-
morphic ventricular tachycardia on holter monitoring, a his-
tory of sudden infant death of her child and without
inducible ventricular arrhythmia by programed ventricular
stimulation [PVS]).
2. Case report
A previously healthy 78-year-old woman was admitted to the
emergency department following recurrent syncopal episodes
with fever, weakness, shortness of breath, and cough symp-
toms. Her son reported that the patient had two episodes of
loss of consciousness. The ﬁrst episode lasted about 1–2 minFigure 1 (A) A 12-lead ECG, recorded while the patient was febr
consistent with a type-I (coved) Brugada ECG pattern. (B) ECG, take
(saddle-back) Brugada ECG pattern.and the patient regained consciousness without confusion soon
afterward. The second episode occurred 5 min after the ﬁrst
episode while the patient was sitting on the bed. The son de-
nied that she had any accompanying seizure activity. Her past
medical history was normal and she denied taking any drugs or
having chest pain.
During the initial physical examination, she was alert,
blood pressure was 105/70 mmHg, heart rate was 80 beats/
min, and body temperature was 39.0 C. Cardiac auscultation
showed normal heart sounds with no murmur or friction rub.
Chest auscultation revealed bilateral rhonchi and inspiratory
crackles in the right lower lung. The neurological examination
was normal. Initial laboratory data showed leukocytosis
(14,400/mm3), elevated C-reactive protein (189 mg/l), and nor-
mal blood chemistry, including potassium (4.3 mEq/L), cal-ile, showing downsloping ST-segment elevation in leads V1–V2,
n several hours after the alleviation of fever, converted to a type-2
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CK-MB). The chest X-ray showed hazy inﬁltrates in the
right lower lung. A cranial computed tomography was
unremarkable, except for cerebral atrophy. A 12-lead ECG
(Fig. 1A), recorded while the patient was febrile (temperature
39.0 C), showed downsloping ST-segment elevation in
leads V1–V2, consistent with a type-I (coved) Brugada ECG
pattern.
She was transferred to the cardiac intensive care unit for
continuous ECG monitoring and was treated with intravenous
paracetamol. A second ECG (Fig. 1B) taken several hours
after the alleviation of fever, converted to a type-2 (saddle-
back) Brugada ECG pattern. An echocardiogram showed nor-
mal systolic function and the absence of segmental wall motion
abnormalities. Her family history was signiﬁcant for the sud-
den unexplained infant death (9 months of age) of her son.
Ambulatory ECG monitoring showed monomorﬁc short-run
ventricular tachycardia. Pneumonia was healed with an antibi-
otic (Ceftriaxone) and an antipyretic (Paracetamol) for
10 days. The patient was diagnosed with BrS and as the patient
had syncope and a positive family history of sudden cardiac
death, an implantable cardioverter deﬁbrillator (ICD) implan-
tation was suggested. Because of these factors, together with
her age and her request that an ICD not be implanted, a sub-
sequent electrophysiological study (EPS) was performed for
risk stratiﬁcation and no ventricular arrhythmias were in-
duced. Quinidine was administered and the patient was recom-
mended to receive urgent antipyretic treatment for fever that
might induce Brugada-like ECG changes. Electrocardiogram
screenings were negative for consenting family members. One
year after her discharge, the patient remained alive and free
of cardiac events and syncope.
3. Discussion
BrS is deﬁnitively diagnosed when a type 1 ST-segment eleva-
tion is observed in >1 right precordial lead (V1–V3) in the
presence or absence of a sodium channel-blocking agent and
one of the following: documented ventricular ﬁbrillation
(VF), polymorphic ventricular tachycardia (VT), a family his-
tory of sudden cardiac death at <45 years old, coved-type
ECGs in family members, inducibility of VT with programed
electrical stimulation, syncope, or nocturnal agonal respira-
tion.2 A new consensus document deﬁnes only two ECG pat-
terns to be considered. Type 1 is identical to the classic type
1 described in the previous consensus, although the new type
2 pattern combines patterns 2 and 3 of the previous consen-
sus.4 The syndrome predisposed to malignant ventricular
arrhythmias generally manifests in men and during adulthood.
It is reported that the youngest patient with the BrS was two
days old and the oldest was 84.3 Infants with an unidentiﬁable
cause after a postmortem investigation are labeled as having
suffered from sudden infant death syndrome (age <1 year)
(SIDS), and it has been reported that an estimated 10% of
SIDS stems from mutations in channelopathy-susceptibility
genes that cause potentially lethal syndromes such as long
QT syndrome, catecholaminergic polymorphic ventricular
tachycardia, and BrS.5 Our patient and her dead son are at
both ends of this range and conﬁrm the association of BrS
and SIDS. Unfortunately, genetic testing was not performed
for our patient.Fever-induced Brugada cases have been previously reported
in the literature. Mutant sodium channels exhibiting tempera-
ture-dependent gating changes have been reported to give rise
to fever-induced ventricular arrhythmias in BrS by signiﬁ-
cantly reducing the sodium currents in the hyperthermic
state.6,7 Junttila et al. reported that regardless of the existence
of a predisposing genetic base, most of their patients with fever
and a Brugada-type ECG developed malignant arrhythmias
shortly after the onset of the fever.8 Thus, fever that can un-
mask BrS and precipitate symptoms associated with malignant
arrhythmias, as it did in our patient, should be treated rapidly
with antipyretics in these patients.
A polymorphic VT is most commonly associated with the
BrS. Monomorphic VT is rarely observed and is more preva-
lent in children.9,10 In contrast, our patient displayed short-
run monomorphic VT during a 24-h Holter ECG monitoring.
Symptomatic patients displaying the type 1 Brugada ECG
(spontaneously or after a drug challenge) who present with
aborted sudden death are at a high risk for recurrence and they
should receive an ICD without an additional need for EPS.2
The guidelines also recommend that patients with a clinical
picture of arrhythmia-mediated syncope or nocturnal agonal
respiration and a type 1 ST-segment elevation should receive
the protection of an ICD after noncardiac causes of these
symptoms have been carefully ruled out.2 The patient was rec-
ommended for an ICD implantation according to the current
guidelines. Because of these factors, together with her age
and the request of the patient that an ICD not be implanted,
a subsequent EPS was performed for risk stratiﬁcation,
although the role of PVS in BrS is controversial11,12 and no
ventricular arrhythmias were induced. As in our case, fever-in-
duced BrS cases undergoing EPS, which failed to induce ven-
tricular arrhythmia despite the presence of the symptoms,13–
15 have been described in the literature and the role of PVS re-
mains a challenge in this population.
Our patient did not receive an ICD and so low-dose quin-
idine (550 mg) was administered orally. Quinidine’s effective-
ness has been demonstrated to prevent VT/VF induction by
PVS16,17 and concluded as a therapeutic option, though its
long-term efﬁcacy in the prevention of SCD has not been stud-
ied. One year after discharge, our patient remained alive and
free of cardiac events and syncope.
In conclusion, BrS should be kept in mind not only in
young male patients, but also in women and older patients
who present with fever and symptoms associated with malig-
nant arrhythmias and ST elevations. The fever should be trea-
ted rapidly with antipyretics as it can precipitate VT/VF. Risk
stratiﬁcation remains a challenge and the role of PVS needs to
be evaluated in fever-induced BrS. Further clinical evaluations
are needed to establish the effectiveness of quinidine in BrS as
an alternative to an ICD.
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